Research Topics
| M-A PeralesSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantationMiguel Angel Perales
Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Blood 120:4882-91. 2012..Our results indicate that r-hIL-7 can enhance immune recovery after a T cell-depleted allo-HSCT without causing significant GVHD or other serious toxicity (www.clinicaltrials.gov; NCT00684008)...
Melanoma vaccinesMiguel Angel Perales
Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford I Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Cancer Invest 20:1012-26. 2002..In this review, we will discuss strategies to induce active immunity against melanoma...- Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCTM A Perales
Allogeneic Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Bone Marrow Transplant 45:1408-16. 2010..Furthermore, the sAAIPI can predict outcomes and may be used to select the most appropriate patients for this type of transplant... - Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host diseaseM A Perales
Allogeneic Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Bone Marrow Transplant 40:481-6. 2007..Careful patient selection and aggressive prophylaxis against viral and fungal infections are recommended... - DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantationMiguel Angel Perales
Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Immunol 177:4159-67. 2006..These results demonstrate that DNA immunization against tissue-restricted Ags after allogeneic T cell-depleted HSCT can induce potent antitumor effects without causing GVHD... - Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domainsCristina R Ferrone
The Swim Across America Laboratory, Memorial Sloan-Kettering Cancer Center, Weill Medical and Graduate Schools of Cornell University, New York, NY 10021, USA
Clin Cancer Res 12:5511-9. 2006.... - T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulinAnn A Jakubowski
Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
Blood 110:4552-9. 2007..Life-threatening OIs occurred in 3 of 52 patients and was fatal in 1. This study demonstrates durable engraftment with a low incidence of GvHD despite the lack of ATG, as well as the curative potential of this regimen... - Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignanciesTrudy N Small
Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Biol Blood Marrow Transplant 13:235-44. 2007..For 18 patients with MDS (< or = RAEB-2) or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%. These data demonstrate the curative potential of this regimen in patients with high-risk myeloid malignancies... - Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplantsDana Jaffe
Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Blood 108:2470-5. 2006.... - Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunityAdam D Cohen
Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Res 66:4904-12. 2006..Finally, this effect on vaccine-induced CD8(+) T-cell responses was partially independent of CD4(+) T cells (both helper and regulatory), consistent with a direct costimulatory effect on the effector CD8(+) cells themselves... - Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particlesStacie M Goldberg
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 11:8114-21. 2005..The purpose of this study was to compare viral and plasmid DNA in combination vaccination strategies in the context of a tumor antigen... - CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systemsPolly D Gregor
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Vaccine 22:1700-8. 2004..Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration... - Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantationJohannes L Zakrzewski
Department of Medicine, Zuckerman Research Center 1404, Mailbox 111, New York, New York 10021, USA
Nat Med 12:1039-47. 2006..We conclude that the adoptive transfer of OP9-DL1-derived T-cell precursors markedly enhances T-cell reconstitution after transplantation, resulting in GVT activity without GVHD... - Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccinesDavid Z Chang
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Hematology 9:207-15. 2004..GM-CSF is an attractive vaccine adjuvant because of its immune modulation effects and low toxicity profile. The results in animal models have been confirmed in pilot clinical trials and several clinical trials are currently ongoing... - GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccinesMiguel Angel Perales
The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cytokines Cell Mol Ther 7:125-33. 2002..These results have implications for understanding early events in the immune response to DNA vaccines, and provide a basis for development of new approaches to cancer vaccines, including the use of cytokine genes as adjuvants... - Strategies to overcome immune ignorance and toleranceMiguel Angel Perales
Memorial Sloan Kettering Cancer Center and Weill Medical School and Graduate School of Cornell University, New York, NY 10021, USA
Semin Cancer Biol 12:63-71. 2002..Crucial to these approaches is the discovery and understanding of the molecular identity of antigens and the mechanisms involved in tumor immunity. In this review, strategies to overcome immune ignorance and tolerance are discussed... - CD4 help and tumor immunity: beyond the activation of cytotoxic T lymphocytesMiguel-Angel Perales
Ann Surg Oncol 11:881-2. 2004
Research Grants
- Optimizing T cell Immunity to Cancer VaccinesMiguel Angel Perales; Fiscal Year: 2006..This environment maximizes the potential for the principal investigator to establish a successful independent research program. ..